These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 1022441)
1. [Estrogen therapy as a cause of experimental and clinical pyelonephritis]. Leĭzerukov EM Eksp Khir Anesteziol; 1976; (4):47-50. PubMed ID: 1022441 [No Abstract] [Full Text] [Related]
2. [Cardiovascular complications during the estrogen therapy of prostatic cancer patients]. Gonchar MA; Popov AI Urol Nefrol (Mosk); 1985; (2):31-3. PubMed ID: 3992753 [No Abstract] [Full Text] [Related]
3. [The cardiovascular and thromboembolic complications of intravital estrogen therapy in middle-aged and elderly patients with prostatic cancer]. Gorilovskiĭ LM; Makarova GV; Nekliudova VI; Shkhvatsabaia LV Urol Nefrol (Mosk); 1992; (1-3):11-5. PubMed ID: 1413332 [TBL] [Abstract][Full Text] [Related]
4. [Diagnosis and therapeutic correction of changes in the cardiovascular system of patients with prostatic cancer treated with estrogens]. Gembitskiĭ EV; Portnoĭ AS; Begunov AV Klin Med (Mosk); 1990 Dec; 68(12):41-5. PubMed ID: 2084339 [TBL] [Abstract][Full Text] [Related]
5. [Porphyria cutanea tarda following treatment with depot estrogens in patients with prostate cancer]. Linss G; Schmechel C Z Urol Nephrol; 1990 May; 83(5):229-31. PubMed ID: 2392882 [TBL] [Abstract][Full Text] [Related]
6. [Hormone therapy for prostatic neoplasms--(1)prognosis, cause of death and estrogen therapy]. Katayama K; Momose G Horumon To Rinsho; 1975 Jul; 23(7):697-702. PubMed ID: 1170990 [No Abstract] [Full Text] [Related]
7. [Estrogen popular again in prostatic cancer?]. Hedlund PO Lakartidningen; 1992 Oct; 89(42):3467-9. PubMed ID: 1435047 [No Abstract] [Full Text] [Related]
8. [The assessment of the state of the blood lipid spectrum, hemostasis, hormonal homeostasis and hemodynamics in the early diagnosis and drug correction of the cardiovascular changes in prostatic cancer patients undergoing estrogen therapy]. Portnoĭ AS; Begunov AV Urol Nefrol (Mosk); 1992; (1-3):6-11. PubMed ID: 1413345 [TBL] [Abstract][Full Text] [Related]
9. [Thyroid hormones in metastasizing prostate cancer treated with polyestradiol phosphate]. Dunzendorfer U; Schulz H Z Urol Nephrol; 1982 Jul; 75(7):493-500. PubMed ID: 6183845 [TBL] [Abstract][Full Text] [Related]
10. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma. Lindstedt E Scand J Urol Nephrol Suppl; 1980; 55():95-7. PubMed ID: 6938044 [TBL] [Abstract][Full Text] [Related]
11. Cholesterol ester metabolism in plasma during estrogen and antiandrogen treatment in men with carcinoma of the prostate. Wallentin L; Varenhorst E J Lab Clin Med; 1981 Dec; 98(6):906-16. PubMed ID: 6458644 [TBL] [Abstract][Full Text] [Related]
13. [What is the function of estrogen receptors in the prostate?]. Jockenhövel F Urologe A; 2003 Jan; 42(1):97. PubMed ID: 14655645 [No Abstract] [Full Text] [Related]
14. Prostatic carcinoma cured with hormonal treatment. A report of two cases. Johansson S; Ljunggren E Scand J Urol Nephrol; 1981; 15(3):321-2. PubMed ID: 7323757 [No Abstract] [Full Text] [Related]
15. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group. Aro J; Ruutu M; Juusela H; Hansson E; Permi J Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869 [TBL] [Abstract][Full Text] [Related]
16. Orchiectomy, estrogen therapy and radiotherapy in locally advanced (T3-4 M0) prostatic cancer. Aro J; Haapiainen R; Kajanti M; Rannikko S; Alfthan O Scand J Urol Nephrol Suppl; 1988; 110():103-7. PubMed ID: 3187397 [TBL] [Abstract][Full Text] [Related]
17. The effects of endocrine therapy on plasma steroids in prostatic carcinoma patients. Drafta D; Proca E; Schindler AE; Neacşu E; Zamfir V; Neagoe M; Teodosiu D Endocrinologie; 1984; 22(3):191-7. PubMed ID: 6494786 [TBL] [Abstract][Full Text] [Related]